Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform

Vaccine

Volumn 25, Issue 30 SPEC. ISS., 2007, Pages 5606-5612

  Poulet, Hervé ^a   Minke, Jules ^a   Pardo, Maria Camila ^a   Juillard, Véronique ^a   Nordgren, Bob ^a   Audonnet, Jean Christophe ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Canarypox virus; Vaccine; Vector

Indexed keywords

CANARYPOX VIRUS VECTOR; RECOMBINANT CANARYPOX VIRUS VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VETERINARY DRUG; VIRUS VACCINE; VIRUS VECTOR;

ARTICLE; BIOSAFETY; CAT DISEASE; CELLULAR IMMUNITY; DOG DISEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SYNTHESIS; DRUG TARGETING; EUROPEAN UNION; GENE EXPRESSION; GENETIC STABILITY; HORIZONTAL GENE TRANSFER; HORSE; HUMAN; HUMORAL IMMUNITY; INFLUENZA; INJECTION SITE INFLAMMATION; LICENCE; MAMMAL; NONHUMAN; PRIORITY JOURNAL; RABIES; REGISTRATION; REPEATED DRUG DOSE; RISK ASSESSMENT; SINGLE DRUG DOSE; TARGET ORGANISM; TRANSGENE; UNITED STATES; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS RECOMBINATION;

EID: 34447098796     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.11.066     Document Type: Article

References (57)

1. Chang Y.F., Appel M.J., Jacobson R.H., Shin S.J., Harpending P., Straubinger R., et al. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect Immun 63 9 (1995) 3543-3549
2. Marciani D.J., Kensil C.R., Beltz G.A., Hung C.H., Cronier J., and Aubert A. Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. Vaccine 9 2 (1991) 89-96
3. Rau H., Revets H., Balmelli C., McCullough K.C., and Summerfield A. Immunological properties of recombinant classical swine fever virus NS3 protein in vitro and in vivo. Vet Res 37 1 (2006) 155-168
4. van Drunen Little, and van den Hurk S. Rationale and perspectives on the success of vaccination against bovine herpesvirus-1. Vet Microbiol 113 3-4 (2006) 275-282
5. Lorenzen N., and LaPatra S.E. DNA vaccines for aquacultured fish. Rev Sci Tech Off Int Epiz 24 1 (2005) 201-213
6. Blancou J., Kieny M.P., Lathe R., Lecocq J.P., Pastoret P.P., Soulebot J.P., et al. Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature 322 6077 (1986) 373-375
7. Brochier B., Blancou J., Thomas I., Languet B., Artois M., Kieny M.P., et al. Use of recombinant vaccinia-rabies glycoprotein virus for oral vaccination of wildlife against rabies: innocuity to several non-target bait consuming species. J Wildl Dis 25 4 (1989) 540-547
8. Mackowiak M., Maki J., Motes-Kreimeyer L., Harbin T., and Van Kampen K. Vaccination of wildlife against rabies: successful use of a vectored vaccine obtained by recombinant technology. Adv Vet Med 41 (1999) 571-583
9. Taylor J., Weinberg R., Kawaoka Y., Webster R.G., and Paoletti E. Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine 6 6 (1988) 504-508
10. Taylor J., Trimarchi C., Weinberg R., Languet B., Guillemin F., Desmettre P., et al. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 9 3 (1991) 190-193
11. Taylor J., Weinberg R., Languet B., Desmettre P., and Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 6 6 (1988) 497-503
12. Huang Z., Elankumaran S., Yunus A.S., and Samal S.K. A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. J Virol 78 18 (2004) 10054-10063
13. Fischer L., Tronel J.P., Pardo-David C., Tanner P., Colombet G., Minke J., et al. Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge. Vaccine 20 29-30 (2002) 3485-3497
14. Darteil R., Bublot M., Laplace E., Bouquet J.F., Audonnet J.C., and Riviere M. Herpesvirus of turkey recombinant viruses expressing infectious bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV virulent challenge in chickens. Virology 211 2 (1995) 481-490
15. Mellencamp M.W., Long M.T.L., Gibbs P.E.G., Seino K.S.S., Beachboard S.E.B., and Zhang S. Safety and efficacy of a live West-Nile virus chimera vaccine using a model of induced West-Nile virus clinical disease. Abstracts from International Veterinary Vaccines and Diagnostics Conference (2006) 139
16. Webster D.P., Dunachie S., McConkey S., Poulton I., Moore A.C., Walther M., et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24 15 (2006) 3026-3034
17. Barouch D.H., and Nabel G.J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16 2 (2005) 149-156
18. Perri S., Greer C.E., Thudium K., Doe B., Legg H., Liu H., et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 77 19 (2003) 10394-10403
19. Schleiss M.R., Bernstein D.I., Passo M., Parker S., Meric C., Verdier F., et al. Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects. Vaccine 23 5 (2004) 687-692
20. Johnson D.C., McFarland E.J., Muresan P., Fenton T., McNamara J., Read J.S., et al. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. J Infect Dis 192 12 (2005) 2129-2133
21. Levy Y., Durier C., Lascaux A.S., Meiffredy V., Gahery-Segard H., Goujard C., et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 20 3 (2006) 405-413
22. Karanikas V., Lurquin C., Colau D., van Baren N., De Smet C., Lethe B., et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 171 9 (2003) 4898-4904
23. Ullenhag G.J., Frodin J.E., Mosolits S., Kiaii S., Hassan M., Bonnet M.C., et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response. Clin Cancer Res 9 7 (2003) 2447-2456
24. van Baren N., Bonnet M.C., Dreno B., Khammari A., Dorval T., Piperno-Neumann S., et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 23 35 (2005) 9008-9021
25. Spaner D.E., Astsaturov I., Vogel T., Petrella T., Elias I., Burdett-Radoux S., et al. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer 106 4 (2006) 890-899
26. Nacsa J., Radaelli A., Edghill-Smith Y., Venzon D., Tsai W.P., Morghen C de G., et al. Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques. Vaccine 22 5-6 (2004) 597-606
27. Paillot R., Kydd J.H., Sindle T., Hannant D., Edlund Toulemonde C., Audonnet J.C., et al. Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus. Vet Immunol Immunopathol 112 3-4 (2006) 225-233
28. Tartaglia J., Jarrett O., Neil J.C., Desmettre P., and Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol 67 (1993) 2370-2375
29. Poulet H., Brunet S., Boularand C., Guiot A.L., Leroy V., Tartaglia J., et al. Efficacy of a canarypox virus-vectored vaccine against feline leukaemia. Vet Rec 153 (2003) 141-145
30. Hofmann-Lehmann R., Tandon R., Boretti F.S., Meli M.L., Willi B., Cattori V., et al. Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays. Vaccine 24 8 (2006) 1087-1094
31. Flynn J.N., Dunham S.P., Watson V., and Jarrett O. Longitudinal analysis of feline leukemia virus-specific cytotoxic T lymphocytes: correlation with recovery from infection. J Virol 76 (2002) 2306-2315
32. El Garch H., Richard S., Piras F., Leard T., Poulet H., Andréoni C., et al. Feline leukemia virus (FeLV) specific IFNγ+ T-cell responses are induced in cats following transdermal vaccination with recombinant FeLV vaccine. Int J Appl Res Vet Med 4 2 (2006) 100-108
33. Backer R.J. Feline fibrosarcomas in vaccination sites. Feline Pract 26 (1998) 18-20
34. Siger L., Bowen R.A., Karaca K., Murray M.J., Gordy P.W., Loosmore S.M., et al. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. Am J Vet Res 65 11 (2004) 1459-1462
35. Edlund Toulemonde C., Daly J., Sindle T., Guigal P.M., Audonnet J.C., and Minke J.M. Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom. Vet Rec 156 12 (2005) 367-371
36. Pardo M.C., Bauman J.E., and Mackowiak M. Protection of dogs against canine distemper by vaccination with a Canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins. Am J Vet Res 58 8 (1997) 833-836
37. Haase C.J., Hageny T.L., Larson L.J., and Schultz R.D. Advantages of using a recombinant canarypox vectored canine Distemper virus vaccine instead of modified live canine Distemper vaccine. Conference of Research Workers in Animal Disease (2006)
38. Grosenbaugh D.A., Backus C.S., Karaca K., Minke J.M., and Nordgren R.M. The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine. Vet Ther 5 4 (2004) 251-257
39. Grosenbaugh D.A., Leard T., and Pardo M.C. Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine. J Am Vet Med Assoc 228 5 (2006) 726-727
40. Minke J.M., Siger L., Karaca K., Austgen L., Gordy P., Bowen R., et al. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl 18 (2004) 221-230
41. De Bruyn G., Rossini A.J., Chiu Y.L., Holman D., Elizaga M.L., Frey S.E., et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 22 5-6 (2004) 704-713
42. Durchfeld B., Baumgartner W., Herbst W., and Brahm R. Vaccine-associated canine distemper infection in a litter of African hunting dogs (Lycaon pictus). Zentralbl Veterinarmed B 37 3 (1990) 203-212
43. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety. Proc Natl Acad Sci USA 93 (1996) 11341-11348
44. Taylor J., Meignier B., Tartaglia J., Languet B., VanderHoeven J., Franchini G., et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 13 6 (1995) 539-549
45. Weli S.C., Nilssen O., and Traavik T. Avipoxvirus multiplication in a mammalian cell line. Virus Res 109 1 (2005) 39-49
46. Tartaglia J., Perkus M.E., Taylor J., Norton E.K., Audonnet J.C., Cox W.I., et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188 (1992) 217-232
47. Chantrey J., Meyer H., Baxby D., Begon M., Bown K.J., Hazel S.M., et al. Cowpox: reservoir hosts and geographic range. Epidemiol Infect 122 3 (1999) 455-460
48. Jourdier T.M., Moste C., Bonnet M.C., Delisle F., Tafani J.P., Devauchelle P., et al. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Ther 10 26 (2003) 2126-2132
49. Moingeon P. Recombinant cancer vaccines based on viral vectors. Dev Biol (Basel) 116 (2004) 117-122
50. Boone J.D., Balasuriya U.B., Karaca K., Audonnet J.C., Yao J., He L., et al. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 25 4 (2007) 672-678
51. Weingartl H.M., Berhane Y., Caswell J.L., Loosmore S., Audonnet J.C., Roth J.A., et al. Recombinant nipah virus vaccines protect pigs against challenge. J Virol 80 16 (2006) 7929-7938
52. Tellier M.C., Pu R., Pollock D., Vitsky A., Tartaglia J., Paoletti E., et al. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats. AIDS 12 1 (1998) 11-18
53. Rogers W.O., Baird J.K., Kumar A., Tine J.A., Weiss W., Aguiar J.C., et al. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect Immun 69 9 (2001) 5565-5572
54. Stephensen C.B., Welter J., Thaker S.R., Taylor J., Tartaglia J., and Paoletti E. Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection. J Virol 71 2 (1997) 1506-1513
55. Plotkin S.A., Cadoz M., Meignier B., Meric C., Leroy O., Excler J.L., et al. The safety and use of canarypox vectored vaccines. Dev Biol Stand 84 (1995) 165-170
56. Menon A.G., Kuppen P.J., van der Burg S.H., Offringa R., Bonnet M.C., Harinck B.I., et al. Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther 10 7 (2003) 509-517
57. Triozzi P.L., Strong T.V., Bucy R.P., Allen K.O., Carlisle R.R., Moore S.E., et al. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther 16 1 (2005) 91-100